Oak Asset Management LLC Sells 50 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Oak Asset Management LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,810 shares of the biopharmaceutical company’s stock after selling 50 shares during the period. Oak Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,742,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock valued at $7,762,577,000 after acquiring an additional 39,780 shares during the period. Capital World Investors raised its stake in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after acquiring an additional 23,146 shares during the period. Putnam Investments LLC raised its stake in Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after acquiring an additional 24,329 shares during the period. Norges Bank bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $932,571,000. Finally, Morgan Stanley raised its stake in Regeneron Pharmaceuticals by 2.7% in the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after acquiring an additional 25,792 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 787 shares of the stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the transaction, the chief executive officer now owns 64,198 shares of the company’s stock, valued at $65,162,253.96. The disclosure for this sale can be found here. Insiders sold a total of 61,971 shares of company stock worth $61,217,654 in the last ninety days. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $1,051.03 on Monday. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $688.52 and a twelve month high of $1,081.17. The company has a market cap of $115.81 billion, a P/E ratio of 31.05, a P/E/G ratio of 2.17 and a beta of 0.13. The business has a fifty day simple moving average of $984.27 and a 200 day simple moving average of $951.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on REGN. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. Finally, JPMorgan Chase & Co. upped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Monday, June 17th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,027.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.